{"id":"NCT04101721","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","officialTitle":"Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-30","primaryCompletion":"2022-08-18","completion":"2022-08-18","firstPosted":"2019-09-24","resultsPosted":"2023-07-20","lastUpdate":"2023-07-20"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Retinopathy of Prematurity"],"interventions":[{"type":"DRUG","name":"aflibercept","otherNames":["EYLEA®","REGN3","VEGF trap-eye","BAY86-5321"]},{"type":"PROCEDURE","name":"laser photocoagulation","otherNames":[]}],"arms":[{"label":"Aflibercept Group","type":"EXPERIMENTAL"},{"label":"Laser Group","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurrence of ROP in the study and to assess the safety and tolerability of aflibercept.","primaryOutcome":{"measure":"Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age","timeFrame":"Baseline to week 52 of chronological age","effectByArm":[{"arm":"Laser Photocoagulation","deltaMin":77.8,"sd":null},{"arm":"Aflibercept 0.4 mg","deltaMin":79.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":52,"countries":["United States","Bulgaria","Colombia","Czechia","Hungary","Romania","Russia","Slovakia","South Korea","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":27},"commonTop":["Constipation","Pyrexia","Gastrooesophageal reflux disease","Inguinal hernia","Bronchopulmonary dysplasia"]}}